Stock Scorecard
Stock Summary for Perspective Therapeutics Inc (CATX) - $3.93 as of 4/30/2026 1:59:31 PM EST
Total Score
7 out of 30
Safety Score
27 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CATX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CATX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CATX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CATX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for CATX (27 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 3 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 1 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for CATX
Financial Details for CATX
Company Overview |
|
|---|---|
| Ticker | CATX |
| Company Name | Perspective Therapeutics Inc |
| Country | N/A |
| Description | Perspective Therapeutics Inc. (CATX) is an innovative biotechnology company dedicated to transforming cancer treatment through the development of advanced radiopharmaceuticals. Harnessing cutting-edge radioisotope technologies, CATX aims to improve the precision and efficacy of cancer therapies, ultimately enhancing patient survival rates across a spectrum of malignancies. With a robust leadership team and strategic partnerships, the company is well-positioned to spearhead breakthroughs in targeted cancer treatments, addressing critical healthcare needs in a highly competitive sector. |
| Sector Name | HEALTHCARE |
| Industry Name | MEDICAL DEVICES |
| Most Recent Quarter | 12/31/2025 |
| Next Earnings Date | 5/11/2026 |
Stock Price History |
|
| Last Day Price | 3.93 |
| Price 4 Years Ago | 2.47 |
| Last Day Price Updated | 4/30/2026 1:59:31 PM EST |
| Last Day Volume | 1,237,478 |
| Average Daily Volume | 1,415,708 |
| 52-Week High | 6.16 |
| 52-Week Low | 1.96 |
| Last Price to 52 Week Low | 100.51% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 25.52 |
| Sector PE | 54.72 |
| 5-Year Average PE | -12.57 |
| Free Cash Flow Ratio | 14.56 |
| Industry Free Cash Flow Ratio | 21.82 |
| Sector Free Cash Flow Ratio | 23.21 |
| Current Ratio Most Recent Quarter | 5.17 |
| Total Cash Per Share | 0.27 |
| Book Value Per Share Most Recent Quarter | 2.78 |
| Price to Book Ratio | 2.35 |
| Industry Price to Book Ratio | 4.19 |
| Sector Price to Book Ratio | 9.07 |
| Price to Sales Ratio Twelve Trailing Months | 509.47 |
| Industry Price to Sales Ratio Twelve Trailing Months | 3.92 |
| Sector Price to Sales Ratio Twelve Trailing Months | 26.78 |
| Analyst Buy Ratings | 12 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 114,018,000 |
| Market Capitalization | 448,090,740 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 2.42% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -30.07% |
| Reported EPS 12 Trailing Months | -1.41 |
| Reported EPS Past Year | 0.00 |
| Reported EPS Prior Year | -1.40 |
| Net Income Twelve Trailing Months | -103,121,000 |
| Net Income Past Year | -103,121,000 |
| Net Income Prior Year | -79,279,000 |
| Quarterly Revenue Growth YOY | -43.40% |
| 5-Year Revenue Growth | -100.00% |
| Operating Margin Twelve Trailing Months | -92,633.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 30,629,000 |
| Total Cash Past Year | 30,629,000 |
| Total Cash Prior Year | 61,580,000 |
| Net Cash Position Most Recent Quarter | 29,060,000 |
| Net Cash Position Past Year | 29,060,000 |
| Long Term Debt Past Year | 1,569,000 |
| Long Term Debt Prior Year | 1,625,000 |
| Total Debt Most Recent Quarter | 1,569,000 |
| Equity to Debt Ratio Past Year | 0.99 |
| Equity to Debt Ratio Most Recent Quarter | 0.99 |
| Total Stockholder Equity Past Year | 207,031,000 |
| Total Stockholder Equity Prior Year | 290,668,000 |
| Total Stockholder Equity Most Recent Quarter | 207,031,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -89,496,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.78 |
| Free Cash Flow Past Year | -95,233,000 |
| Free Cash Flow Prior Year | -72,708,000 |
Options |
|
| Put/Call Ratio | 0.14 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 2.11 |
| 20-Day Bollinger Middle Band | 4.05 |
| 20-Day Bollinger Upper Band | 5.98 |
| Beta | 1.87 |
| RSI | 50.03 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 5.66 |
System |
|
| Modified | 5/1/2026 7:26:00 PM EST |